A majority-owned subsidiary of Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) in Colombia has received certification that will allow it export cannabis biomass to a number of its international clients, and furthers the firm’s goal of GMP certification and sale to European markets.
In an statement Thursday, the company said its subsidiary Santa Marta Golden Hemp S.A.S. has met global standards of Good Agricultural and Collection Practices (GACP), and can start expand its raw cannabis materials brand Aureus Santa Marta to include biomass and flower.
According to the firm, Aureus — which includes a range of cannabinoids and standardized genetics offerings — has been successfully exported to 11 countries.
With the GACP certification, Avicanna says it’s also one step closer to getting its European GMP extraction certification, which the company plans on getting next year.
“This achievement adds to our 3 years of optimization, the ideal climate conditions and robust genetics of our cultivation practices which combined further fortify the clear competitive advantages of our global raw material business unit,” said Avicanna LATAM president Lucas Nosiglia in a statement.
“Coupled with the new regulatory framework in Colombia which would authorize the export of flower, we will now deliver GACP and organic certified flower from our greenhouse and outdoor modalities to the global market.”
Currently, the company can produce around 30,000 kilograms of biomass per year at its cultivation facility in Santa Marta. The firm says it’s plan is to establish a low-cost, sustainable and standardized supply chain business with global standards including GACP and United States Department of Agriculture National Organic Program certifications.
Avicanna’s raw material suppliers are based in Santa Marta, Colombia. Through its Colombian subsidiaries, cannabis extracts and feminized seeds have been sold to customers in countries including Brazil, Peru and the United States.
The company conducts research at its headquarters in Toronto, and has advanced the development of pharmaceutical-grade cannabis products including RHO Phyto and cosmetic brand Pura H&W.
It currently has drug candidates in pre-clinical trials involving cannabis-based medicine to reduce epileptic seizures and sudden death.